For research use only. Not for therapeutic Use.
SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1].
SCO-267 (CHO cells) activates the Gαq, Gαs, and Gα12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1].
SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1].
| Catalog Number | I036137 |
| CAS Number | 1656261-09-4 |
| Synonyms | (3S)-3-cyclopropyl-3-[2-[[1-[2-[2,2-dimethylpropyl-(6-methylpyridin-2-yl)carbamoyl]-5-methoxyphenyl]piperidin-4-yl]methoxy]pyridin-4-yl]propanoic acid |
| Molecular Formula | C36H46N4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C36H46N4O5/c1-24-7-6-8-32(38-24)40(23-36(2,3)4)35(43)29-12-11-28(44-5)20-31(29)39-17-14-25(15-18-39)22-45-33-19-27(13-16-37-33)30(21-34(41)42)26-9-10-26/h6-8,11-13,16,19-20,25-26,30H,9-10,14-15,17-18,21-23H2,1-5H3,(H,41,42)/t30-/m0/s1 |
| InChIKey | VVRXREQIOCYUKN-PMERELPUSA-N |
| SMILES | CC1=NC(=CC=C1)N(CC(C)(C)C)C(=O)C2=C(C=C(C=C2)OC)N3CCC(CC3)COC4=NC=CC(=C4)C(CC(=O)O)C5CC5 |
| Reference | [1]. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293. |
